Prognostic Outcomes of Tall Cell Variant Papillary Thyroid Cancer: A Meta-Analysis by Jalisi, Scharukh et al.
SAGE-Hindawi Access to Research
Journal of Thyroid Research
Volume 2010, Article ID 325602, 4 pages
doi:10.4061/2010/325602
Research Article
PrognosticOutcomesofTallCellVariantPapillaryThyroid
Cancer:A Meta-Analysis
ScharukhJalisi,1 Tifﬁny Ainsworth,2 andMichaelLaValley3
1Department of Otolaryngology, Head and Neck Surgery, Boston University School of Medicine, 820 Harrison Avenue,
FGH4, Boston MA 02118, USA
2Department of Otolaryngology, University of Connecticut, Farmington, CT 06262, USA
3Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
Correspondence should be addressed to Scharukh Jalisi, scharukh.jalisi@bmc.org
Received 17 January 2010; Accepted 24 June 2010
Academic Editor: David Goldenberg
Copyright © 2010 Scharukh Jalisi et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To evaluate the prognosis of tall cell variant (TCV) compared to usual variant (UV) papillary thyroid cancer by
comparing disease-related mortality and recurrence data from published studies. Methods. Ovid MEDLINE keyword search using
“tallcellvariantpapillarythyroidcancer”wasusedtoidentifystudiespublishedinEnglishthatcalculateddisease-relatedmortality
and recurrence rates for both TCV and UV. Results. A total of 131 cases of tall cell variant papillary thyroid cancer were reviewed.
The combined odds ratio of recurrence for TCV compared to UV is 4.50 with a 95% conﬁdence interval from 2.90 to 6.99. For
disease-related mortality, the combined odds ratio for TCV was compared to UV of 14.28 with a 95% conﬁdence interval from
8.01 to 25.46. Conclusion. Currently published data suggests that TCV is a negative prognostic indicator in papillary thyroid cancer
and requires aggressive therapy. This meta-analysis provides the largest prognostic data series on TCV in the literature and clearly
identiﬁes the need for accurate pathological identiﬁcation of TCV and its further study as an independent prognostic factor.
1.Introduction
Tall cell variant papillary thyroid carcinoma (TCV) was ﬁrst
described in 1976 by Hawk and Hazard as an aggressive
histological variant of papillary thyroid cancer [1]. TCV is
deﬁned as tall papillary epithelial cells with a height at least
twice the width and basement membrane oriented nuclei
comprising at least 30% of the cells within the tumor [1–3].
Usualvariantpapillarythyroidcancerdescribesconventional
papillary thyroid carcinoma composed of papillary epithelial
cells arranged in papillae with ﬁbrovascular cores without
excessive height compared to cell width. The published
incidence of TCV is between 3.8% and 10.4% [1, 4–10].
Unlike the usually good prognosis of usual variant papillary
thyroid cancer (UV), TCV histology is generally reported as
an independently poor prognostic factor [1, 3, 5, 6, 8, 9].
More recently reported case series do not show that
TCV histology adversely aﬀects prognosis [7, 10, 11]. One
such large retrospective study concluded the poor prognosis
of TCV tumors was not particularly related to histology
but to factors such as stage and grade [10]. Another case
series found the higher rate of recurrence in TCV was
strictly associated with age over 50 [7]. Although these
more recent studies improved on previously reported studies
by increasing the sample sizes, the number of TCV cases
still remain small in comparison to the UV group. A
reason for the low TCV numbers could be misclassiﬁcation
bias where the diagnosis of TCV is missed by routine
pathologic examination. As ﬁrst described in a case series
of 162 papillary thyroid cancers, initial routine pathological
examinationfailedtodetect8outof11casesofTCV[4].The
additionaleightcaseswerediscoveredonlybyanexperienced
pathologist with a special interest in thyroid pathology and
familiar with TCV histology. As larger sample sizes are
studied, the potential for misclassiﬁcation bias also increases.
This may lead to erroneous comparisons of recurrence and
mortality data between TCV and UV.
The purpose of this meta-analysis is to evaluate the
prognostic impact of TCV histology in papillary thyroid
cancer in currently published studies by comparing TCV2 Journal of Thyroid Research
Table 1
Study Mean age Mean tumor
size (cm)
%p o s i t i v el y m p h
nodes
% extra-thyroidal
extension
% distant
metastasis % recurrence % disease-related
mortality
Johnson
TCV (n = 12) 49.4 2.8 75 42 17 58.3 25
NV (n = 12) 48.3 2.3 42 0 0 8.3 0
Michels
TCV (n = 56) 50 2 37.5 39 8 14.3 12.5
NV (n = 503) 45.6 1.5 23 9 2.6 5.4 1.6
Moreno Egea
TCV (n = 5) 65.4 ≥2.86∗ 80 100 20 80 20
NV (n = 85) 41.5 NA∗∗ 34.1 14.1 NA∗∗ 16.5 1.2
Prendiville
TCV (n = 20) 49.6 2.1 40 65 NA∗∗ 20 5
NV
(n = 1355∗∗∗) 35.7 2.5 39 8 NA∗∗ 15 2
Segal
TCV (n = 19) NA∗∗ NA∗∗ NA∗∗ NA∗∗ NA∗∗ 47.4 73.7
NV (n = 223) NA∗∗ NA∗∗ NA∗∗ NA∗∗ NA∗∗ 9.9 3.6
Terry
TCV (n = 19) NA∗∗ 4.2 NA∗∗ NA∗∗ NA∗∗ 35.3 5.9
NV (n = 118) NA∗∗ 2.8 NA∗∗ NA∗∗ NA∗∗ 3.8 0.8
∗The size of two tumors reported >4cm.
∗∗Not Available.
∗∗∗Article used NV data from Mazzaferri and Jhiang [12].
and UV disease-related mortality and recurrence data. We
hypothesizethatthecumulativepublishedevidencesupports
TCV as a negative prognostic factor as measured by a greater
disease-related mortality and recurrence rate than UV.
2. Methods
A systematic literature review was conducted on May 23,
2007utilizingtheOvidsearchenginetoaccesstheMEDLINE
database. Articles from January 1, 1980 to May 23, 2007
were evaluated. The term “tall cell variant papillary thyroid
cancer” was used as a keyword search and yielded 108
articles. The titles and abstracts were carefully reviewed and
thoseevaluatingtheprognosticimplicationofTCVhistology
in papillary thyroid cancer were included for review. The
papers were evaluated based on predetermined inclusion
and exclusion criteria and their references were reviewed for
additionally relevant papers. The primary inclusion criterion
was studies that compared prognostic factors in TCV to UV
papillary thyroid cancer. Exclusion criteria included those
with total sample size less than or equal to 15, non-English
reports, and the absence of recurrence and disease-related
mortality data for both TCV and UV groups. The MEDLINE
andbibliographysearchafterapplicationoftheinclusionand
exclusion criteria yielded six reports that were included in
our study (Table 1).
All statistical analyses were performed by a single statisti-
cian. Both odds ratios and 95% conﬁdence intervals for both
recurrence and disease-related mortality were calculated for
each of the studies. In the case of a 0 count in a study,
0.5 was added to all the counts for that study to allow
calculation of an odds ratio and 95% conﬁdence interval.
The next step determined the combined odds ratio of all six
studiesforrecurrenceanddisease-related mortality. Both the
ﬁxed eﬀects Cochran-Mantel-Haenszel and a random eﬀects
method for binary data were used to calculate combined
odds ratios. A ﬁxed eﬀects method gives each study a
weighting in accordance to the precision of its estimate
whereas a random eﬀects method accounts for variation
between studies by giving a relatively larger weight to the less
precise studies.
For both the odds of recurrence and mortality, a test for
heterogeneity that accompanies the ﬁxed eﬀects, Cochran-
Mantel-Haenszel model was signiﬁcant (P = .023 and P
= .033, resp.) suggesting that between-study variability was
t o og r e a tf o raﬁ x e de ﬀects model. As a result, the random
eﬀects method to determine the odds ratio was preferred to
account for the extra variation between studies.
3. Results
After application of our inclusion and exclusion criteria, six
articleswereavailableforreview(Table 1).ThestudybySegal
et al. and Terry et al. was included due to the presence of
recurrence and mortality data. The total number of TCV
cases for review in our study was 131. This allows for our
study to have the largest number of TCV cases available for
evaluation in the literature to the best of our knowledge.Journal of Thyroid Research 3
T h em e a na g ea td i a g n o s i so fT C Vw a sg r e a t e rt h a n4 5
years. No data on gender predilection could be determined
from the studies. Mean tumor size was comparable to the
tumor size in UV papillary thyroid cancer. Reviewing the
data from [3, 8–10], the TCV patients had a higher rate
of extrathyroidal extension (cumulative average of 60.33%
patients) and higher rate of distant metastases at diagnosis
(cumulative average of 15%). In addition, the cumulative
average of lymph node metastases in TCV cases is 58.12%
versus 34.5% in UV cases. The percentage of recurrence and
disease-related mortality is also noted to be higher in TCV
group versus UV group. The cumulative average recurrence
in TCV group is 42.5% versus 9.8% in UV group. The
cumulative average disease-related mortality in TCV group
is 23.6% versus 1.5% for UV group.
The odds ratios calculated by this study for recurrence
and disease-related mortality are provided in Table 2.A l l
of the individual study’s odds ratios demonstrate a greater
odds of recurrence in the TCV subjects compared to the
UV subjects. The odds ratios are statistically signiﬁcant
in all the studies except the Prendiville et al. study [8].
All the calculated odds ratios for individual study disease-
related mortality similarly demonstrated an increased rate of
disease-related mortality in TCV subjects compared to UV
subjects; however, only three of the six studies [6, 9, 10]
had statistically signiﬁcant odds ratios where the conﬁdence
interval did not include one.
The combined odds ratios for recurrence and disease-
related mortality using both the ﬁxed and random eﬀects
methods are provided in Table 3. The test for heterogeneity
(P = .023) that accompanies the random eﬀects method in
determining the odds of recurrence indicates the random
eﬀect method would be preferable to account for the extra
between-study variation by giving a relatively larger weight
to the less precise studies. Although both combined odds
ratios of recurrence demonstrate a greater rate of recurrence
in the TCV subjects compared to UV subjects, the preferred
random eﬀects model odds ratio suggests that recurrence
occurs with 4.50 times greater odds in TCV tumors versus
UV tumors and that this is statistically signiﬁcant (95% CI
2.90–6.99).
Similarly, the combined odds of disease-related mortality
is greater for TCV subjects compared to UV subjects
regardless of whether a ﬁxed versus random eﬀects method
is used. Using the preferred random eﬀects model, the odds
of disease-related mortality in TCV patients are 14.28 times
greater than UV patients. This is also statistically signiﬁcant
(95% CI: 8.01–25.46).
4. Discussion
TCV is a negative prognostic indicator in papillary thyroid
cancer.Byperformingameta-analysisonpublishedresearch,
we hoped to overcome the limitations of small sample sizes
of individual articles to examine the impact of such a rare
histological subtype on prognosis. The total number of TCV
cases in our analysis are 131. To summarize, we found
TCV recurs with 4.50 times greater odds than UV. This
Table 2
Study
Recurrence Odds Ratio
[95% Conﬁdence
Interval]
Disease-related
Mortality Odds Ratio
[95% Conﬁdence
Interval]
Johnson 15.4 [1.47–160.97] 9.21 [0.42–200.34]
Michels 2.94 [1.26–6.83] 8.84 [3.07–25.41]
Moreno Egea 20.29 [2.11–195.38] 21.00 [1.10–400.30]
Prendiville 1.42 [0.47–4.29] 2.59 [0.33–20.4]
Segal 8.22 [3.02–22.40] 75.25 [21.75–260.36]
Terry 13.85 [3.64–52.76] 8.19 [0.49–137.36]
Table 3
Recurrence [95%
conﬁdence interval]
Disease-related
mortality [95%
conﬁdenceinterval]
Fixed eﬀects
model 4.61∗ [2.94–7.22] 16.47# [8.86–30.60]
Random eﬀects
model 4.50 [2.90–6.99] 14.28 [8.01–25.46]
∗Test for between-study heterogeneity statistically signiﬁcant (P = .023).
#Test for between-study heterogeneity statistically signiﬁcant (P = .033).
is statistically signiﬁcant with a 95% conﬁdence interval
between 2.90 and 6.99. Additionally, we found TCV has
a 14.28 times greater disease-related odds of mortality
compared to UV. This is statistically signiﬁcant with a 95%
conﬁdence interval between 8.01 and 25.46. We also noted
higher trends in lymph node metastasis, distant metastasis,
and extrathyroidal extension in TCV patients versus UV
patients.
The adverse eﬀects of TCV on prognosis, as represented
by our study, necessitate a careful and perhaps more aggres-
sive approach than typically followed with UV. Whereas
partial thyroidectomy (deﬁned as thyroid lobectomy with
or without isthmusectomy) is an acceptable conservative
approach to patients with low-risk UV for recurrence and
mortality (by AMES criteria), our research suggests a more
aggressive approach for TCV (e.g., total thyroidectomy with
central neck dissection) may be indicated. The problem at
hand is that TCV is detected at pathological evaluation,
which occurs after the initial thyroid surgery has been
performed. Hence, we propose that if a newly diagnosed
patient with TCV has undergone partial thyroidectomy, then
the patient should return to the operating room for at least
a completion thyroidectomy and central neck dissection
followed by radioactive iodine ablation of residual tissue.
If a total thyroidectomy was performed at initial surgery,
then careful consideration should be given for return to the
operating room for a central neck dissection (depending on
surgeon experience) followed by radioactive iodine ablation
versus radioactive iodine ablation alone. If the tumor is
not radioactive iodine avid, then early intervention with
external beam radiation should be considered. Additional
issues, such as longer follow-ups and extensive screening for
distant metastasis, may also be warranted. A recent review of4 Journal of Thyroid Research
papillarythyroidcancervariantsrecommendedanaggressive
approach to TCV [13]w i t ha tl e a s tat o t a lt h y r o i d e c t o m y .
In a recent matched-pair analysis comparing TCV
patients to the matched UV cohort, 5-year disease speciﬁc
survival was poorer in the TCV cohort (81.9% versus 91.3%,
P = .049). The number of deaths in the TCV cohort was
higher than in the matched Papillary thyroid cancer cohort
(P = .043) [14]. This study further aﬃrms the results of our
study showing higher rate of recurrence and mortality in
TCV patients.
Our results stress the necessity of accurate pathological
diagnosis. Since the discovery of TCV in 1976, the ability to
study and evaluate the prognostic implications of histology
in papillary thyroid cancer resides solely on accurate patho-
logical identiﬁcation. Hence, there is no substitute for an
experienced pathologist in the management of this disease.
There are several limitations in our study. Firstly, we
have large conﬁdence intervals which reﬂect the variation
between studies and the relatively small number of studies
included in the meta-analysis. This is also reﬂected in the
test of heterogeneity that we performed that directed us to
use the random eﬀects model rather than the ﬁxed eﬀects
model. In addition, the articles by Segal et al. [6]a n dT e r r y
et al. [7] did not have data on patient age, tumor size,
lymph node metastasis, extrathyroidal extension, or distant
metastases. These articles were included due to the presence
of recurrence and disease-related mortality data. Good faith
eﬀortsweremadetocontacttheauthorsforthisdatawithout
success.
5. Conclusions
In conclusion, the data supports TCV as a poor prognostic
factor as determined by disease-related mortality and recur-
rencerates.Asaresult,thisdatasupportsearlyaggressivesur-
gical and adjuvant radioactive iodine management and the
necessity for accurate pathologic diagnosis. It unequivocally
supports the absolute need for further study of TVC as an
independent prognostic factor in future studies on papillary
thyroid cancer.
References
[1] W. A. Hawk and J. B. Hazard, “The many appearances
of papillary carcinoma of the thyroid,” Cleveland Clinic
Quarterly, vol. 43, no. 4, pp. 207–216, 1976.
[2] M. J. Merino and C. Monteagudo, “Tall cell carcinoma of the
thyroid: an aggressive variant of papillary cancer,” Pathology
Case Reviews, vol. 2, pp. 196–199, 1997.
[ 3 ]T .L .J o h n s o n ,R .V .L l o y d ,N .W .T h o m p s o n ,W .H .B e i e r -
waltes, and J. C. Sisson, “Prognostic implications of the tall
cell variant of papillary thyroid carcinoma,” American Journal
of Surgical Pathology, vol. 12, no. 1, pp. 22–27, 1988.
[4] A. R¨ uter, R. Nishiyama, and S. Lennquist, “Tall-cell variant of
papillary thyroid cancer: disregarded entity?” World Journal of
Surgery, vol. 21, no. 1, pp. 15–21, 1997.
[5] R. A. Ghossein, R. Leboeuf, K. N. Patel et al., “Tall cell variant
of papillary thyroid carcinoma without extrathyroid exten-
sion:biologicbehaviorandclinicalimplications,”Thyroid,vol.
17, no. 7, pp. 655–661, 2007.
[6] K.Segal,R.Fridental,E.Lubin,J.Shvero,J.Sulkes,andR.Fein-
messer, “Papillary carcinoma of the thyroid,” Otolaryngol—
Head and Neck Surgery, vol. 113, pp. 356–363, 1995.
[ 7 ]J .H .T e r r y ,S .A .S t .J o h n ,F .J .K a r k o w s k ie ta l . ,“ T a l lc e l l
papillary thyroid cancer: incidence and prognosis,” American
Journal of Surgery, vol. 168, no. 5, pp. 459–461, 1994.
[8] S. Prendiville, K. D. Burman, M. D. Ringel et al., “Tall cell
variant: an aggressive form of papillary thyroid carcinoma,”
Otolaryngology—Head and Neck Surgery, vol. 122, no. 3, pp.
352–357, 2000.
[9] A. Moreno Egea, J. M. Rodriguez Gonzalez, J. Sola Perez, T.
SoriaCogollos,andP.ParrillaParicio,“Prognosticvalueofthe
tall cell variety of papillary cancer of the thyroid,” European
Journal of Surgical Oncology, vol. 19, no. 6, pp. 517–521, 1993.
[10] J. J. Michels, M. Jacques, M. Henry-Amar, and S. Bardet,
“Prevalence and prognostic signiﬁcance of tall cell variant of
papillary thyroid carcinoma,” Human Pathology, vol. 38, no. 2,
pp. 212–219, 2007.
[11] T. Hefer, H. Z. Joachims, A. Eitan, and M. Munichor, “Are the
morphology of papillary thyroid carcinoma and the tumour’s
behaviourcorrelated?”JournalofLaryngologyandOtology,vol.
110, no. 7, pp. 704–705, 1996.
[12] E. L. Mazzaferri and S. M. Jhiang, “Long-term impact of
initial surgical and medical therapy on papillary and follicular
thyroid cancer,” American Journal of Medicine, vol. 97, no. 5,
pp. 418–428, 1994.
[13] T. Carling, I. T. Ocal, and R. Udelsman, “Special variants of
diﬀerentiated thyroid cancer: does it alter the extent of surgery
versus well-diﬀerentiated thyroid cancer?” World Journal of
Surgery, vol. 31, no. 5, pp. 916–923, 2007.
[14] L. G. Morris, A. R. Shaha, R. M. Tuttle, A. G. Sikora, and
I. Ganly, “Tall-cell variant of papillary thyroid carcinoma: a
matched-pair analysis of survival,” Thyroid,v o l .2 0 ,n o .2 ,p p .
153–158, 2010.